Not so fast: FDA tacks 3 more months onto decision date for Calliditas' rare kidney disorder drug
It looks like the FDA’s decision on Calliditas’ IgA nephropathy candidate Nefecon is going to take a few months longer than expected — allowing time for rivals like Martin Shkreli’s former company Travere Therapeutics to catch up.
Five months after granting Nefecon priority review, the FDA is extending its PDUFA date from Sept. 15 to Dec. 15, Calliditas announced on Tuesday. The Swiss biotech filed for accelerated approval back in March, based on data from 200 patients in the first part of the Phase III NefIgArd trial who showed a significant reduction in proteinuria, or excessive protein in the urine.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.